Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca’s Lynparza. The drug addresses a $1.4-billion U.S. market opportunity. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation.Read More
Punjab National Bank shares rose sharply on Monday after the PSU lender reported a 214% YoY jump in Q1FY27 net profit, beating Street estimates. Strong asset quality, lower provisions and improving margins prompted JM Financial to upgrade the stock and Motilal Oswal to reiterate its Buy rating with a higher target.Read More
Kotak Mahindra Bank shares fell after reporting a strong profit increase for the first quarter. Net profit rose 26% year-on-year, and net interest income also saw growth. Asset quality improved from the previous year, though key ratios weakened sequentially. Brokerages provided varied ratings, with some reiterating buy recommendations and others maintaining add ratings. Analysts cited...Read More
SBI Funds Management is set to debut on the NSE and BSE on July 21, with the grey market indicating an around 18% listing premium over the IPO price. The Rs 9,813-crore IPO attracted strong investor interest, with the issue being subscribed 41.66 times during the July 14–16 bidding period.Read More
Six stocks in the Nifty500 segment that gained over 2.5% featured in the RSI Trending Up scan on July 17 after showing improving momentum. The RSI moved above the 50 mark from lower levels, signalling strengthening price action, improving sentiment and potential short-term buying opportunities for traders tracking bullish technical setups.Read More
On July 17, five stocks in the Nifty500 pack rallied more than 1.5% above their Volume Weighted Average Price (VWAP), according to StockEdge’s technical scan data. Trading above the VWAP is widely regarded as a bullish technical signal, reflecting strong buying interest and indicating the potential for further upside.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
